U.S. National Institute of Health informed in its statement on Thursday that it would be stopping the HIV experimental vaccine study that was launched in 2009.
More than 2,500 people from 19 cities were enrolled in “HVTN 505 Clinial Trial” since its kick-off. The participants were males who reported having sex with other males and trans-gender people who engaged in sexual relations with men.
They were separated into two groups one of which received the new vaccine developed by NIH, and the other was given placebo vaccination. The participants of the study had been regularly monitored through scheduled check-ups.
The latest safety review performed on April 22 showed that the numbers of volunteers infected with HIV were slightly higher in the first vaccinated group than in the placebo group.
Particularly, 41 people from the vaccinated group and 30 people from the placebo group have been infected since the experiment started.
NHI structural department, National Institute of Allergy and Infectious Diseases, stressed that discrepancy between results is not statistically significant and should be considered accidental.
The review results demonstrated that the vaccine did not produce any HIV resistance, and was ineffective in reducing “viral load” in the infected individuals who had contracted HIV and were monitored for more than 20 weeks of follow-up.
The trial has been called off, although the participants' health will be monitored further. Over recent years, several different vaccines have failed in trials, and a few more are currently being studied.
NIH summarized in its statement, “NIAID remains committed to the pursuit of a highly effective, preventive HIV vaccine as part of a multifaceted HIV prevention research program”.
|Weekly consumption of oily fish rich in ... The essential omega-3 fatty acid abundant in oily fish ...|